Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PRR013
MIFTS: 37

Prurigo Nodularis

Categories: Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Prurigo Nodularis

About this section

MalaCards integrated aliases for Prurigo Nodularis:

Name: Prurigo Nodularis 20 54 71 32
Nodular Prurigo 20

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

ICD10 32 L28.1
UMLS 71 C0263353
Sources

Summaries for Prurigo Nodularis

About this section
GARD : 20 Prurigo nodularis (PN) is a skin disease that causes hard, itchy lumps (nodules) to form on the skin. The itching (pruritus) can be intense, causing people to scratch themselves to the point of bleeding or pain. Scratching can cause more skin lesions to appear. The itching is worsened by heat, sweating, or irritation from clothing. In some cases, people with PN have a history of other diseases including eczema (atopic dermatitis), lymphoma, HIV infection, severe anemia, or kidney disease. The exact cause of PN is unknown. Although scratching is known to cause more nodules to appear, it is unclear what causes the itching to develop in the first place. Diagnosis of the disease is based on observing signs such as extremely itchy skin with the formation of nodules. In some cases, a skin biopsy is used to confirm the diagnosis. Treatment may include corticosteroid creams, oral medications, cryotherapy, or photochemotherapy.

MalaCards based summary : Prurigo Nodularis, also known as nodular prurigo, is related to skin disease and dermatitis, atopic. An important gene associated with Prurigo Nodularis is RNASE3 (Ribonuclease A Family Member 3), and among its related pathways/superpathways are PAK Pathway and NF-KappaB Family Pathway. The drugs Nalbuphine and Serlopitant have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and endothelial, and related phenotype is renal/urinary system.

Wikipedia : 74 Prurigo nodularis (PN), also known as nodular prurigo, is a skin disease characterised by pruritic... more...

Sources

Related Diseases for Prurigo Nodularis

About this section

Diseases related to Prurigo Nodularis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 183)
# Related Disease Score Top Affiliating Genes
1 skin disease 30.5 TAC1 RNASE3 NGFR IL17A
2 dermatitis, atopic 30.3 TAC1 RNASE3 NGF IL17A
3 anhidrosis 30.0 NGFR NGF
4 proteasome-associated autoinflammatory syndrome 1 30.0 RNASE3 IL17A
5 peripheral nervous system disease 29.9 TAC1 NGFR NGF IL17A
6 neuroma 29.8 SEMA3A NGF
7 pulmonary disease, chronic obstructive 29.8 TAC1 RNASE3 IL17A
8 disease of mental health 28.2 TAC1 SEMA3A NGFR NGF IL17A EDN1
9 amyloidosis, primary localized cutaneous, 1 11.1
10 epidermolysis bullosa pruriginosa 11.1
11 amyloidosis, primary localized cutaneous, 2 11.1
12 amyloidosis, primary localized cutaneous, 3 11.1
13 dermatitis 10.5
14 neurodermatitis 10.5
15 pemphigoid 10.4
16 keratosis 10.4
17 neuropathy 10.4
18 vitiligo-associated multiple autoimmune disease susceptibility 6 10.3
19 vitiligo-associated multiple autoimmune disease susceptibility 1 10.3
20 bullous pemphigoid 10.3
21 lichen planus 10.3
22 ige responsiveness, atopic 10.3
23 contact dermatitis 10.3
24 keratoacanthoma 10.3
25 pustulosis of palm and sole 10.3
26 psoriasis 10.3
27 hypereosinophilic syndrome 10.3
28 lymphoma, hodgkin, classic 10.2
29 leprosy 3 10.2
30 exanthem 10.2
31 allergic disease 10.2
32 allergic contact dermatitis 10.2
33 uremia 10.2
34 chronic kidney disease 10.2
35 scabies 10.2
36 herpes zoster 10.2
37 vasculitis 10.2
38 hansen's disease 10.2
39 timothy grass allergy 10.1 RNASE3 IL17A
40 vasomotor rhinitis 10.1 TAC1 RNASE3
41 cystic echinococcosis 10.1 RNASE3 IL17A
42 echinococcosis 10.1 RNASE3 IL17A
43 conjunctival disease 10.1 RNASE3 IL17A
44 churg-strauss syndrome 10.1 RNASE3 IL17A
45 transient refractive change 10.1 TAC1 EDN1
46 cough variant asthma 10.1 RNASE3 NGF
47 ocular cicatricial pemphigoid 10.1 RNASE3 NGF
48 paranasal sinus disease 10.1 RNASE3 IL17A
49 ocular dominance 10.0 NGFR NGF
50 common cold 10.0 RNASE3 IL17A

Graphical network of the top 20 diseases related to Prurigo Nodularis:



Diseases related to Prurigo Nodularis
Sources

Symptoms & Phenotypes for Prurigo Nodularis

About this section

MGI Mouse Phenotypes related to Prurigo Nodularis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.02 EDN1 IL17A NGFR SEMA3A TAC1
Sources

Drugs & Therapeutics for Prurigo Nodularis

About this section

Drugs for Prurigo Nodularis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nalbuphine Approved Phase 2, Phase 3 20594-83-6 5360630 5311304
2 Serlopitant Investigational Phase 3 860642-69-9
3 Neurotransmitter Agents Phase 3
4 neurokinin A Phase 3
5 Neurokinin-1 Receptor Antagonists Phase 3
6
Substance P Phase 3 33507-63-0 44359816
7 Narcotics Phase 2, Phase 3
8 Analgesics, Opioid Phase 2, Phase 3
9 Analgesics Phase 2, Phase 3
10 Pharmaceutical Solutions Phase 3
11 Calcineurin Inhibitors Phase 3
12
Apremilast Approved, Investigational Phase 2 608141-41-9 11561674
13
Pimecrolimus Approved, Investigational Phase 2 137071-32-0 6447131 17753757
14
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
15
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
16
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
17 Anti-Inflammatory Agents Phase 2
18 Analgesics, Non-Narcotic Phase 2
19 Anti-Inflammatory Agents, Non-Steroidal Phase 2
20 Antirheumatic Agents Phase 2
21 Immunosuppressive Agents Phase 2
22 Immunologic Factors Phase 2
23 Dermatologic Agents Phase 2
24 Hydrocortisone 17-butyrate 21-propionate Phase 2
25 Hydrocortisone hemisuccinate Phase 2
26 Hydrocortisone-17-butyrate Phase 2
27
Citalopram Approved 59729-33-8 2771
28
Levoleucovorin Approved, Investigational 68538-85-2 149436
29
Dapsone Approved, Investigational 80-08-0 2955
30
Folic acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
31 Antidepressive Agents
32 Serotonin Uptake Inhibitors
33 Psychotropic Drugs
34 Anti-Infective Agents
35 Vitamin B Complex
36 Folic Acid Antagonists
37 Antiparasitic Agents
38 Antiprotozoal Agents
39 Folate
40 Vitamin B9
41 Antimalarials
42 Anti-Bacterial Agents
43
Serotonin Investigational, Nutraceutical 50-67-9 5202

Interventional clinical trials:

(show all 19)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients Completed NCT02174419 Phase 2, Phase 3 nalbuphine HCl ER tablets 90 mg BID;nalbuphine HCl ER tablets 180 mg BID;Placebo tablets BID
2 An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients Completed NCT02174432 Phase 2, Phase 3 nalbuphine HCl ER
3 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis Completed NCT03546816 Phase 3 5mg Serlopitant Tablets;Placebo Tablets
4 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis Completed NCT03677401 Phase 3 5mg Serlopitant Tablets;Placebo Tablets
5 A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm , Efficacy and Safety Study in Prurigo Nodularis (PN) With Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study) Recruiting NCT03497975 Phase 2, Phase 3 Nalbuphine ER Tablets
6 A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis Recruiting NCT04204616 Phase 3 Nemolizumab
7 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis Recruiting NCT04501679 Phase 3 Nemolizumab;Placebo
8 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis Recruiting NCT04501666 Phase 3 Nemolizumab 30 mg;Placebo
9 A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable Recruiting NCT04202679 Phase 3 Dupilumab SAR231893;Placebo;Moisturizers;Low to medium potent topical corticosteroids;Topical calcineurin inhibitors
10 A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable Recruiting NCT04183335 Phase 3 Dupilumab SAR231893;Placebo;Moisturizers;Low to medium potent topical corticosteroids;Topical calcineurin inhibitors
11 Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis Unknown status NCT03576287 Phase 1, Phase 2 Apremilast Oral Product
12 Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease Completed NCT00507832 Phase 2 Pimecrolimus;Hydrocortisone;Pimecrolimus
13 An Open Label, Single Center Study to Assess the Safety and Efficacy of a 24 Week Treatment Course of CC-10004 in Adults With Recalcitrant Nodularis Completed NCT00869089 Phase 2 CC-10004
14 A Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis (PN) Completed NCT03181503 Phase 2 CD14152 Dose A;CD14152 placebo
15 A Randomized, Double-Blind, Placebo-Controlled, Study of Neurokinin-1 Receptor Antagonist Serlopitant in Subjects With Prurigo Nodularis Completed NCT02196324 Phase 2 serlopitant;Placebo
16 A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis Recruiting NCT03816891 Phase 2 vixarelimab;Placebo
17 Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis Unknown status NCT00532519 citalopram (cipralex)
18 A Double-blind, Randomized, Parallel-group, Side-by-side Single-center Study Comparing a Topical Steroid / Vehicle Combination to a Topical Steroid / Topical Dapsone Combination in Patients With Lichen Simplex Chronicus and/or Prurigo Nodularis Unknown status NCT01870050 Dapsone gel - verum
19 Transcriptomic Landscape of T Lymphocytes of Atopic Dermatitis, Atopic Prurigo Nodularis (of Besnier) and Non-atopic Prurigo Nodularis (of Hyde) Using Single Cell RNA-sequencing Not yet recruiting NCT04681300

Search NIH Clinical Center for Prurigo Nodularis

Sources

Genetic Tests for Prurigo Nodularis

About this section
Sources

Anatomical Context for Prurigo Nodularis

About this section

MalaCards organs/tissues related to Prurigo Nodularis:

40
Skin, T Cells, Endothelial
Sources

Publications for Prurigo Nodularis

About this section

Articles related to Prurigo Nodularis:

(show top 50) (show all 590)
# Title Authors PMID Year
1
Psychiatric disorders and pruritus. 61 20
28511824 2017
2
Treatment of prurigo nodularis with lenalidomide. 61 20
27891738 2017
3
Increased nerve growth factor- and tyrosine kinase A-like immunoreactivities in prurigo nodularis skin -- an exploration of the cause of neurohyperplasia. 54 61
11875644 2002
4
Eosinophil cationic protein- and eosinophil-derived neurotoxin/eosinophil protein X-immunoreactive eosinophils in prurigo nodularis. 61 54
10994770 2000
5
Histamine-containing mast cells and their relationship to NGFr-immunoreactive nerves in prurigo nodularis: a reappraisal. 54 61
9609137 1998
6
Eosinophilic cationic protein (ECP) in skin disorders. 54 61
1685831 1991
7
Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. 61
32682025 2021
8
Alitretinoin for prurigo nodularis. 61
33464627 2021
9
Dupilumab treatment of prurigo nodularis in an adolescent. 61
33586661 2021
10
Real-world disease burden and comorbidities of pediatric prurigo nodularis. 61
33600911 2021
11
Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction. 61
33320272 2021
12
Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review. 61
31693426 2021
13
Pruritus in Black Skin: Unique Molecular Characteristics and Clinical Features. 61
32747312 2021
14
Dupilumab as promising treatment for prurigo nodularis: current evidences. 61
33588666 2021
15
Prurigo nodularis comparative treatment outcome in patients attending a tertiary hospital in northern Tanzania. 61
33559259 2021
16
Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis. 61
33191806 2021
17
Pruritus Intensity Scales across Europe: a prospective validation study. 61
33411947 2021
18
New and emerging treatments for inflammatory itch. 61
32497711 2021
19
Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta. 61
33428793 2021
20
Dermal Periostin: A New Player in Itch of Prurigo Nodularis. 61
33236123 2021
21
The impact of prurigo nodularis on sleep disturbance and related impact: a systematic review. 61
32490566 2020
22
Comment on 'Successful treatment of recalcitrant nodular prurigo with tofacitinib'. 61
32662144 2020
23
Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial. 61
32936233 2020
24
Prurigo nodularis: Pathogenesis and management. 61
32461078 2020
25
Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response. 61
33200955 2020
26
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. 61
33332697 2020
27
Epidermolysis bullosa pruriginosa treated with dupilumab. 61
33336814 2020
28
Prurigo nodularis: Epidemiology and clinical features. 61
32454098 2020
29
Epidemiology of Prurigo Nodularis compared with Psoriasis in Germany: A Claims Database Analysis. 61
33021323 2020
30
Epidermolysis Bullosa Pruriginosa successfully treated with concomitant topical and systemic agents. 61
32524588 2020
31
Phototherapy for Prurigo Nodularis: Our Experience and a Review of the Literature. 61
33221272 2020
32
Dupilumab for pediatric prurigo nodularis: A case report. 61
33247435 2020
33
Oral Alitretinoin for Patients with Refractory Prurigo. 61
33182351 2020
34
[Prurigo nodularis, a therapeutic challenge]. 61
32792208 2020
35
Our experience with prurigo nodularis treated with dupilumab. 61
33232536 2020
36
Dupilumab as a useful treatment option for prurigo nodularis in an elderly patient with atopic diathesis. 61
32562425 2020
37
Prevalence of prurigo nodularis in the United States. 61
32531481 2020
38
Successful treatment of recalcitrant nodular prurigo with tofacitinib. 61
32484964 2020
39
Chronic nodular prurigo: clinical profile and burden. A European cross-sectional study. 61
32078192 2020
40
The impact of prurigo nodularis on quality of life: a systematic review and meta-analysis. 61
33108524 2020
41
Langerhans cell histiocytosis mimicking prurigo nodularis. 61
33040393 2020
42
Association of prurigo nodularis and lichen simplex chronicus with hospitalization for mental health disorders in US adults. 61
32078024 2020
43
A Case Report of Prurigo Nodularis-Like Lesions in a Patient with Lepromatous Leprosy. 61
33362510 2020
44
Prurigo nodularis in vitiligo patches: An unusual observation. 61
32875033 2020
45
[Clinical characteristics of patients with prurigo nodularis: A descriptive study]. 61
32475624 2020
46
Analysis of 325 Patients with Chronic Nodular Prurigo: Clinics, Burden of Disease and Course of Treatment. 61
32556359 2020
47
Trends in the Demographics and Treatment of Prurigo Nodularis in the United States. 61
32496156 2020
48
A case report and differential diagnosis of pruritic pretibial skin lesions. 61
32975304 2020
49
Delusional Infestation Can Be a Complication of Prurigo Nodularis with Underlying Neuropathies. 61
32556345 2020
50
Emergency department utilization by patients with prurigo nodularis in the United States. 61
32622140 2020
Sources

Variations for Prurigo Nodularis

About this section
Sources

Expression for Prurigo Nodularis

About this section
Search GEO for disease gene expression data for Prurigo Nodularis.
Sources

Pathways for Prurigo Nodularis

About this section

Pathways related to Prurigo Nodularis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
PAK Pathway 63
Show member pathways
 12.69 SEMA3A NGFR NGF IL17A
2
NF-KappaB Family Pathway 63
Show member pathways
 12.2 SEMA3A NGFR NGF
3
TNF Superfamily Pathway: Human Ligand-Receptor Interactions and their Associated Functions 64
Show member pathways
 11.37 NGFR NGF
4
Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway 23
Show member pathways
 11.3 NGFR NGF
5
Guidance Cues and Growth Cone Motility 63
11.2 SEMA3A NGFR NGF
6
p75(NTR)-mediated signaling 1
Show member pathways
 11.19 NGFR NGF
7
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 11.13 SEMA3A NGFR NGF IL17A
8
Neurotrophic factor-mediated Trk receptor signaling 1
Show member pathways
 11.04 NGFR NGF
9
14-3-3 and Regulation of BAD Activity 63
10.66 NGFR NGF
Sources

GO Terms for Prurigo Nodularis

About this section

Cellular components related to Prurigo Nodularis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 TAC1 SEMA3A RNASE3 NGF IL17A EDN1
2 axon GO:0030424 9.33 TAC1 SEMA3A NGF
3 extracellular region GO:0005576 9.17 TAC1 SEMA3A RNASE3 NGFR NGF IL17A

Biological processes related to Prurigo Nodularis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.5 TAC1 IL17A EDN1
2 cellular response to interleukin-1 GO:0071347 9.48 IL17A EDN1
3 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.46 NGFR NGF
4 regulation of blood pressure GO:0008217 9.43 TAC1 EDN1
5 sensory perception of pain GO:0019233 9.4 TAC1 EDN1
6 positive regulation of axonogenesis GO:0050772 9.37 NGFR NGF
7 neurotrophin TRK receptor signaling pathway GO:0048011 9.26 NGFR NGF
8 positive regulation of renal sodium excretion GO:0035815 9.16 TAC1 EDN1
9 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 8.96 NGFR NGF
10 nerve development GO:0021675 8.8 SEMA3A NGFR NGF
Sources

Sources for Prurigo Nodularis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....